The company has so far treated patients who were weeks or months away from a transplant, but the device is theoretically suitable for longer-term use.
Bivacor wins FDA breakthrough nod for titanium total artificial heart Read More »
AstraZeneca has put hundreds of millions of dollars into AI deals, with an eye toward not just accelerating the development of drugs that treat cancer after it appears but also in creating diagnostics that can catch cancer earlier than current methods allow.
AstraZeneca Racks Up AI Partners, Seeking To Stop Cancer at All Stages Read More »
Data presented at ASCO show that swapping in the oral drug camizestrant for an older therapy helped sustain the benefit of initial treatment, potentially opening a novel step in patient care.
AstraZeneca drug could help keep a common breast cancer at bay Read More »
Bristol Myers Squibb is dropping at least $3.5 to jointly develop the bispecific antibody, which will race with Summit Therapeutics, Merck and Pfizer in the crowded PD-1/PD-L1xVEGF space.
BMS Commits up to $11B+ To Work With BioNTech on Solid Tumor Bispecific Read More »
Updated Phase I/Ib data in hand, Arcus will launch a Phase III trial as it aims to compete with Merck, whose drug secured approval for a type of kidney cancer in 2023.
Arcus Kidney Cancer Drug Casdatifan Advances to Challenge Merck’s Welireg Read More »
Following Merus’ splash last month with a “best-in-disease profile” for its head and neck cancer bispecific, Bicara touted positive results for its monocolonal antibody, but analysts say Merus still has the upper hand.
Bicara Responds to Rival Merus With Early Survival Data at #ASCO25 Read More »
CEO Sean Saint and CFO Stephen Feider spoke about what’s different now that the company is public and the long journey of pursuing an IPO.
Beta Bionics CEO, CFO on how to take a company public Read More »
Jefferies analysts said the approval was largely expected and an “incremental positive” for Moderna amid questions about the FDA’s attitude toward mRNA and COVID-19 vaccines that have investors worried.
Moderna Wins FDA Approval for Next-Gen COVID-19 Vaccine Despite ‘Investor Nervousness’ Read More »
Unos científicos han conseguido emplear residuos de setas para un dispositivo que transforma la luz en electricidad de forma más eficiente que mediante los sistemas convencionales. El logro es obra de un equipo internacional encabezado por Natalie Flores, de la Universidad de …
Residuos de setas para convertir luz en electricidad Read More »
Hoy en día es habitual la existencia de recursos digitales en las aulas infantiles y su utilización como herramienta para distintos procesos de aprendizaje. Por ejemplo, existen programas informáticos dirigidos a niños y niñas que están aprendiendo a leer y …
